IHS Chemical Week

EnviroTech :: Innovation

DSM Secures Deal to Produce Anti-cancer Drug for Phase III Clinical Trials

10:41 AM MDT | March 13, 2012 | Alex Scott

DSM Pharmaceutical Products has signed a new contract to supply Agennix (Heidelberg, Germany), a biopharma company, with sufficient quantities of talactoferrin, a prototype drug for treating small-cell lung cancer (NSCLC) that is anticipated to move in phase III clinical trials shortly. Financial terms were not disclosed. DSM has been the producer of talactoferrin for batches used in earlier phase clinical trials and has also been responsible for process development. Under the new contract, DSM is also positioned to supply talactoferrin to Agennix should the drug...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa